StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > CIBC and TD lower their targets to 0.40

<< Previous

Bullboard Posts

Next >>

Comment by StockscoutXon Apr 08, 2021 10:12pm

227 Views

Post# 32964548

RE:RE:RE:CIBC and TD lower their targets to 0.40

Research Report from one of the major banks.
Uncertainty : Extreme
Investment Style : Small growth.

The target price or fair price is much lower then $1.25. It's rather in the 0.70s and maybe lower. Just consult the report you get from your bank on any given stock. Again take those reports with a grain of salt because it's only a guide that could be part of your toolbox when making decision to invest or not..

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing